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Abstract We have identified and characterized a genomic DNA
fragment containing the coding sequences corresponding to the
human Q-glutamyltransferase type 1 mRNA. The coding part of
the gene spans over 16 kb and comprises 12 exons and 11 introns
exhibiting a similar organization as for the mouse and rat GGT
genes. The exons 1^7 encode the heavy subunit whereas exons 8^
12 which encode the carboxy-terminal part of the heavy subunit
(exon 8) and the light subunit are clustered in a 1.6-kb BglII
fragment. Exons 7 and 8 are separated by a 3.9-kb intron
containing in its 3P part the sequences corresponding to the 5P-
UTRs of the truncated GGT mRNAs described for human lung.
Sequence analysis upstream this transcribed region exhibited
putative promoter sequences and after transient transfection
significant promoter activities were measured in V79 lung
fibroblasts and KYN-2 hepatoma cells but not in A2780 ovarian
cells. This specificity disappeared when only 550 bp upstream the
transcription start site were used as promoter. These results
argue for a promoter of truncated GGT mRNAs in intron 7,
specifically regulated in human tissues.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Catabolism of glutathione and glutathione conjugates be-
gins with the cleavage of the Q-glutamyl moiety by Q-glutamyl-
transferase (GGT; EC 3.2.2.2), a heterodimeric glycoprotein
which is located at the outer surface of the plasma membrane
[1]. The highest GGT activity is found in the renal proximal
tubules, small intestine, pancreas and other organs or tissues
which have absorptive or secretory functions [2]. It is gener-
ally admitted that GGT participates in the active transport of
amino acids [1] but also in other important biochemical path-
ways, such as detoxi¢cation or in£ammatory responses, by
processing GSH-conjugated electrophiles and leukotrienes
[3,4]. Modulation of GGT activity is known to occur during
development [5], but GGT activity is also elevated in numer-
ous human tissue carcinomas [6,7], in sera from subjects with
malignant diseases [8] and it is modulated during cell di¡er-
entiation [9,10].
GGT is translated from a single mRNA as a single chain
precursor polypeptide which is cleaved into two subunits
(heavy subunit 55^60 kDa, light subunit 21^30 kDa) during
the maturation process [11]. In rat and mouse several GGT
mRNAs, having the same open reading frame (ORF) but
di¡ering in their 5P untranslated regions (5P-UTR), have
been described [12,13]. These mRNAs are transcribed from
a single gene with several tissue speci¢c promoters, each one
controlling the expression of a speci¢c mRNA [14^17].
Human GGT belongs to a multigenic family with at least
7 distinct members [18] mostly localized on chromosome 22
[19]. Type I GGT mRNA encodes for an enzyme with cata-
lytic properties identical to the enzyme puri¢ed from human
tissues [20]. Type I GGT mRNAs isolated from pancreas [21],
placenta [22], fetal liver [23], and HepG2 hepatoma [24] have
the same ORF but di¡er in their 5P-UTR, a situation similar
to the one observed in mouse and rat. These di¡erent 5P-
UTRs would play an important role in the regulation of the
translation of the GGT mRNA [25].
Several truncated GGT mRNAs of V1.2 kb have been
described in lung tissue [26]. One of them presents a coding
sequence identical to the corresponding part of type I mRNA,
has a unique 5P-UTR, and probably is transcribed from the
same gene as the type I mRNA.
A determination of the structure of the human GGT gene is
therefore necessary to elucidate the mechanisms involved in
the generation of these multiple mRNAs. In this paper, we
describe the cloning of the human GGT gene corresponding
to the type I mRNAs and its structure as deduced from the
nucleotide sequence. Furthermore we present evidence that
the truncated mRNAs are transcribed in a tissue speci¢c man-
ner from a promoter contained within intron 7 of this gene.
2. Materials and methods
2.1. Genomic library screening
A human genomic library was generously provided by Dr. M.
Goossens, CreŁteil, France and Dr. C.Y. Lau, San Francisco, USA.
This library was prepared by insertion of MboI partially digested
human genomic DNA at the BamHI site of the cosmid pCV 105.
125 000 clones representing 1.25 copies of the human genome were
screened with the HepG2 cDNA [24] as probe. Clones harboring the
FEBS 20712 27-8-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 9 5 0 - 8
*Corresponding author. Fax: (33) (383) 32 13 22.
E-mail: visvikis@ctrmed.u-nancy.fr
1Present address: Meijo University, Faculty of Pharmacy, Nagoya 468,
Tempaku, Japan.
Abbreviations: GGT, Q-glutamyltransferase; kb, kilobase; UTR, un-
translated region; Denhardt’s, 1% Ficoll, 1% polyvinylpyrolidone, and
1% bovine serum albumin; PCR, polymerase chain reaction; 1USSC,
0.15 M NaCl/0.015 M sodium citrate
The sequence reported here was submitted to EMBL databank under
the accession number Y09833. Additional sequences of the human
GGT gene (5P-UTR exons and coding exons) were submitted under the
accession numbers AJ006806, AJ006854, AJ230125, AJ007378,
AJ007379 and AJ007380.
FEBS 20712 FEBS Letters 434 (1998) 51^56
sequences corresponding to the type I GGT mRNA were identi¢ed by
the PCR/hybridization method developed by Courtay et al. [18].
2.2. Exon-intron structure determination
Puri¢ed cosmid DNA was subjected to restriction mapping and
Southern blot analysis by standard techniques [27]. Three HindIII
restriction fragments (9H1: V4.5 kb, 9H2: V6 kb and 9H3: V7
kb), which hybridized to human GGT cDNA or oligonucleotide
probes derived from the cDNA sequence, were gel puri¢ed and sub-
cloned into pBluescribe or pUC19 vectors. The nucleotide sequence of
the subclones was determined by manual dideoxy sequencing (T7
sequencing kit, Pharmacia), or in the case where some exons were
localized into very large restriction fragments (exons 2^6) they were
directly sequenced by ESGS (Montigny le Bretoneux, France) using
internal primers derived from the cDNA sequence. The particular
intron containing the 5P-UTRs of the truncated GGT mRNAs was
ampli¢ed from the cosmid by PCR using Amp8 (5P-GCAGTCTCTA-
GACCCGGG-3P) and Amp9 (5P-CAAGTTTGTGGATGTGACT-
GA-3P) primers and the ampli¢cation product was subcloned in the
pCRII vector (Invitrogen) for restriction mapping and sequencing.
2.3. RT-PCR analysis
Total RNA from human kidney (2 Wg) and poly(A) mRNA from
human lung (0.5 Wg) (Clontech) were reverse transcribed in 50 Wl
containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2,
1 mM of each dNTP, 40 units RNasin and 200 units of MuMLV
reverse transcriptase (Promega) for 2 h at 37‡C.
Two Wl of the above reaction were used for PCR ampli¢cation as
described [18], either with Amp1-Amp2 primers or with Amp11 (5P-
GGCAGCGAAGAACTCGGAGG-3P, position +4 to +24)-Amp12
(5P-AGGGAGTCAGACTGGTCA-3P, position 3186 to 3170) pri-
mers which were derived from the sequence of the truncated GGT
cDNA [26]. PCR products were analyzed by agarose gel electropho-
resis, blotted and hybridized with the 32P-labelled oligonucleotide 5P-
CTGCCGAGACCCCAGAGCTGGC-3P which hybridizes in the 5P-
UTR (position 313 to 334) of the truncated GGT mRNAs [26].
2.4. GGT-luciferase chimeric plasmids
A 3.6-kb fragment of the particular intron was ampli¢ed from
cosmid DNA by PCR using 2 primers, Amp9S (5P-AGAGCTC-
CAAGTTTGTGGATGTGACTGA-3P) which derives from the
GGT intron sequence and comprises a SacI restriction site in its 5P
end and Amp10 (5P-AAGATCTATACCAGTGTGACTCCCT-3P)
which derives from the sequence of the 5P-UTRs of the truncated
GGT mRNAs and comprises a BglII restriction site in its 5P end
and cloned in the corresponding sites of the pGL3 enhancer vector
(Promega) to construct the pGL3-INT chimeric plasmid. The pGL3-
INT was digested by BglII and BamHI and the V550-bp fragment,
containing the most 3P sequences of the putative promoter, was cloned
in the BglII site of the pGL3 enhancer to construct the pGL3-INTBa
chimeric plasmid.
2.5. Cell culture and transfections
The Chinese hamster lung ¢broblasts V79, the human hepatoma
cell line KYN-2 and the human ovarian cell line A2780 were cultured
in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal
calf serum and 2 mM glutamine. These cells were cotransfected with
2 Wg of a luciferase construct and 0.5 Wg of SV40-L-galactosidase per
well using lipofectamine according to the manufacturer’s protocol.
The cells were cultured for 48^60 h and cell extracts were prepared
by resuspending the cells in 1 ml of 1U Reporter lysis bu¡er (Prom-
ega). Luciferase activity was measured with the luciferase activity
assay kit (Promega). L-Galactosidase activity was determined in every
extract with the L-gal assay kit (Promega) to correct for di¡erences in
transfection e⁄ciency.
3. Results
3.1. Structure of the human GGT gene
134 cosmids containing GGT related sequences were iso-
lated after screening 1.25 copies of a human genomic DNA
library using a HepG2 GGT cDNA [24] as probe. A clone,
named c509, was selected for further studies as: (i) the ampli-
¢cation by PCR using Amp1-Amp2 primers generated 280 bp
which hybridized to type I mRNA speci¢c oligonucleotide
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Fig. 1. Genomic structure of the coding region of human GGT gene. Exons are denoted by solid boxes, the 5P- and 3P-UTR are denoted in
open boxes. Exons and introns are drawn to scale except for introns 1 and 3 where the length is approximative (see also Table 1). Enzymes
used for the restriction maps are: B: BamHI; Bg: BglII; E: EcoRI; E5: EcoRV; H: HindIII; K: KpnI; P: PstI; Sc: SacI; Sm: SmaI;
St: StuI; X: XhoI.
Table 1
Exon-intron organization of the coding region of the human GGT gene
Exon number Positiona 3P splice acceptorb Exon length (bp) 5P splice donorb Junction amino acids Intron length (bp)c
1 37/165 gtgcagCAGAGCCATG 168 GGG AGGgtgagcgg R55 v3000
2 166/295 agGAT GCA 129 ACC ACA Cgtgagtgc R99 134
3 296/382 ccttctagGA AAA GCT 86 CAG AAG Ggtaagcca G128 v3000
4 383/575 agGG GGG CTG 192 GTC TTG TGgtggttat C192 395
5 576/733 tgccccagT GAG GTG 157 GCG GCC Ggt G245 v1500
6 734/884 cattgcagGG GGC ATT 150 CTC AAA GGgt G295 800
7 884/1020 atacggagG TAC AAC 136 ACT GAGgtaagggg E340 W3800
8 1021/1210 cggcagGTG GTC 189 AAC CTC TAgt Y403 216
9 1209/1338 agC TTT GGC 129 CAG CCA Ggtaataga G446 88
10 1337/1449 tgcagcagGG AAG CAG 112 GCA CTGgtatgtgt L483 81
11 1450/1558 tgccccagGCC ATC 108 AAC ATT Ggt D520 286
12 1559-end ctagACCAGG s 300
aExon position is indicated by nt numbers at its 5P and 3P limits according to the published cDNA sequence (accession no. X60069).
bNucleotide sequences across the intron-exon junctions are shown, exon sequences in capital and intron sequences in lower-case letters.
cSizes were determined either by complete sequencing or by estimating the distance between exons on the restriction map.
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[18]; (ii) they hybridized with an oligonucleotide correspond-
ing to nucleotides +1 to +20 of the type I GGT mRNA [21];
(iii) their partial restriction map ¢tted with the corresponding
map of gene 6 [18] (results not shown), and the sequence of
the exons was determined and was found to be 100% identical
to the type I GGT mRNA.
As shown in Fig. 1 cosmid 509 contains all the coding
exons, the 3P-UTR and a part of the 5P-UTR corresponding
to bases 199^480 of the HepG2 GGT mRNA [24]. The coding
sequences of the human GGT gene are divided in 12 exons,
spanning over approximatively 16 kb, and they are arranged
in a similar manner as for the mouse and rat GGT genes
[12,13].
The intron-exon junctions were determined by comparing
the gene and mRNA sequences [21] and are summarized in
Table 1. Exon 1 contains the last 7 bp of the common 5P-
UTR, the ATG start codon, the ¢rst 54 codons and part of
codon 55. Exons 1^7 correspond to the mRNA sequences
encoding for V98% of the heavy subunit and are spread
over 16 kb. Exon 8 encodes for the end of the heavy subunit
and the beginning of the light subunit, where the proteolytic
cleavage of the precursor polypeptide occurs. Exons 9^12 en-
code for the remaining of the light subunit and are comprised
in a 1.6-kb BglII fragment in accordance to Courtay et al.
[18]. Exon no. 12 consists of 151 bp of coding sequence, the
TGA stop codon and the 3P-UTR including the polyadenyla-
tion signal. All the intron-exon junctions are in good agree-
ment with the GT/AG rule.
3.2. Transcription of truncated mRNAs is controled by an
intronic promoter
Exon 7 and exon 8 are separated by a V3.9-kb intron
(intron 7, Fig. 1). Partial sequencing of this intron revealed
that it contained in its 3P end the distinct 5P-UTR of the
truncated GGT mRNAs described for human lung [26]. A
759-bp BamHI-BglII fragment corresponding to the 3P part
of this intron was subcloned and sequenced (Fig. 2).
The value +1 was attributed to the base corresponding to
the ¢rst nucleotide of the truncated mRNAs as described by
Wetmore et al. [26] and was con¢rmed by in vitro transcrip-
tion/primer extension experiments (not shown). Thus bp +1 to
+262 correspond to the 5P-UTR of the truncated GGT
mRNAs and are organized in three regions (Fig. 2): region
A (+1 to +99), region B (+100 to +228) and region C (+229 to
+250), and are separated by GT/AG intron-exon junctions,
consistent with the proposed alternative splicing events at
the origin of various types of truncated GGT mRNA [26].
Upstream of the 5P-UTR there is no TATA box but an A/T
rich ‘TATA-like’ region (AAATATTTTT) centered at 323.
No CAAT boxes are present but consensus sequences for
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Fig. 2. Partial nucleotide sequence of the intronic promoter. Nucleotides are numbered from the ¢rst nucleotide (showed by an arrow) of the
published mRNA sequence [26]. Nucleotides present in the mRNA are printed in bold face. Regions A, B, and C of the 5P-UTR are delimited
by upper solid lines. The ATG initiator is dashed underlined. The A/T rich region is underlined and the GT repeat is double underlined. The
consensus sequences for Sp1 and AP2 transcription factors are in bold italic. The location of Amp11 and Amp12 primers are underlined by ar-
rows.
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potential binding of the Sp1 factor [28] were found at posi-
tions 3355 to 3348 and for the AP2 factor [29] at positions
3435 to 3428, 3320 to 3312 and 3196 to 3189. A GT motif
(TGTGTGTGTTTG) homologous to the core sequence of
many enhancers [30] is found between nucleotides 3120 and
3109.
To ascertain whether the truncated mRNAs arose from
tissue speci¢c splicing of the complete GGT mRNA or from
a distinct promoter we subcloned two DNA fragments in the
reporter pGL3 enhancer vector (Fig. 3A): (i) the whole intron
as ampli¢ed with primers Amp9S and Amp10 (corresponding
to nucleotides +94 to V33600, pGL3-INT); (ii) the V550-
bp fragment corresponding to nucleotides 3454 to +94
(pGL3-INTBa).
V79 lung ¢broblasts transfected with the whole intron
(pGL3-INT) as promoter showed the highest activity (5.5-
fold over the control promoterless pGL3 plasmid) represent-
ing approximately 50% of the luciferase activity driven by the
late SV40 promoter (Fig. 3B). In the same cells the pGL3-
INTBa construct showed a 4-fold enhancement of luciferase
activity. Promoter activity in the KYN-2 hepatoma cells was
also important but less than in the V79 cells, while the pGL3-
INT was ine¡ective in the A2780 ovarian cancer cells. These
results show that this intron exhibits a promoter activity and
that its expression is tissue speci¢c.
3.3. Expression of the truncated mRNAs in lung and kidney
tissues
The tissue expression of the truncated mRNAs was exam-
ined by speci¢c RT/PCR in RNA from human kidney and
lung. As expected Amp1-Amp2 ampli¢cations gave one major
band of 217 bp (Fig. 4A, lanes 2 and 4) for both tissues, while
Amp11-Amp12 ampli¢cation gave a less intense 211 band,
which corresponds well to the theoretical size, and many faint
smaller bands (Fig. 4A, lanes 1 and 3). Upon hybridization
with the probe speci¢c for 5P-UTR of the truncated mRNAs
several bands were revealed. The 211-bp band and a 140-bp
band were present in both tissues, while in lung two additional
bands of 174 bp and 95 bp hybridized with the probe (Fig. 4B,
lanes 1P and 3P). As expected the products from the Amp1-
Amp2 ampli¢cations gave no signal (Fig. 4B, lanes 2P and 4P).
The 211-bp band should correspond to a truncated mRNA
whose 5P-UTR is composed of the regions A, B and C (Fig. 2)
and the 95-bp product could correspond to the 5P-UTR com-
posed of the regions A and C (Fig. 2). These results are in
good agreement with the splicing events proposed by Wet-
more et al. [26]. The additional intermediate fragments of
174 bp and 140 bp indicate that region B cannot be consid-
ered as unique and most probably contains internal splicing
acceptor and donor sites.
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Fig. 3. Analysis of promoter activity by transient expression. A:
Schematic representation of constructs driving the luciferase reporter
gene. B: Analysis of the expression of GGT-luciferase constructs.
Transfections were carried out with the pGL3-INT (F) (a V3.6-kb
insert from the intron used as promoter) or the pGL3-INT B (l)
(V550 bp of the most 3P region of the above fragment) in V79,
KYN-2, and A2780 cells. Each value was corrected for transforma-
tion e⁄ciency as reported in Section 2 and expressed as -fold activ-
ity of the control (promoter-less) pGL3 vector and is the average of
three values obtained from three separate experiments.
Fig. 4. RT-PCR analysis of the expression of the truncated mRNAs in human tissues. A: Ethidium bromide stained gel; st PX174/HaeIII frag-
ments (the bp length is shown on the right); lanes 1 and 2: RT/PCR of human lung poly(A) mRNA; lanes 3 and 4: RT/PCR of human kid-
ney RNA; in lanes 1 and 3 PCR was performed with the Amp11-Amp12 primers speci¢c for the truncated mRNAs; in lanes 2 and 4 PCR
was performed with the Amp1-Amp2 primers. B: Southern blot of the above gel using a 32P-labelled oligonucleotide speci¢c for the truncated
GGT mRNAs; samples in lanes 1P, 2P, 3P and 4P correspond to lanes 1, 2, 3, and 4 in A.
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4. Discussion
We report here the cloning and characterization of the
GGT gene which is ubiquitously expressed in human tissues.
The coding sequence perfectly corresponds to the sequences of
GGT mRNAs isolated from pancreas, placenta, fetal liver and
HepG2 hepatoma [21^24], con¢rming that these mRNAs are
transcripts from the same gene. The coding sequence is di-
vided in 12 exons which are organized in 5 regions containing
exon 1, exons 2 and 3, exons 4 and 5, exons 6 and 7 and exons
8^12, respectively. These regions are separated by large in-
trons (s 1500 bp) whereas within each region the introns
are smaller (6 800 bp). A similar pattern is observed for rat
and mouse GGT genes but the corresponding introns are
smaller than in human [12,13].
In mouse and rat, the di¡erent GGT mRNAs are tran-
scribed from a single gene under the control of multiple tissue
speci¢c promoters [14^17]. This organization leads to the ex-
pression of multiple mRNAs with an identical open reading
frame di¡ering in their 5P-UTR. Furthermore, no truncated
mRNAs have ever been detected in rodent tissues. In human,
the organization of the GGT gene and the presence of
mRNAs di¡ering in their 5P-UTR supposes a similar regula-
tion and expression pattern. The major di¡erence is that al-
tered and/or truncated human GGT mRNAs have been re-
ported.
Such altered GGT mRNAs have ¢rst been described for
fetal and adult liver and were demonstrated to be present in
many other tissues [31,32]. They exhibit a 22-bp insertion
which leads to a premature stop codon and shortens the
open reading frame to 1098 bp in comparison to 1710 bp
for type I mRNAs. These extra 22 bp are localized at the 3P
end of intron 7, con¢rming that these mRNAs are transcribed
from the same gene as the type I mRNAs. Inside these trun-
cated transcripts a second putative open reading frame is ob-
served with its initiation codon in a favorable environment for
the initiation of translation [32]. This second open reading
frame matches perfectly with the one reported for the trun-
cated mRNAs found in lung tissue [26]. In this intron and
upstream of these 22 bp we observed the sequences of the 5P-
UTR of the truncated mRNAs. These sequences contain the
three adjacent regions A, B, and C observed in the cDNA
sequence [26] and which are not interrupted by introns. Com-
plex splicing events seem to take place in a tissue speci¢c
manner resulting in a marked heterogeneity of this 5P-UTR.
By speci¢c PCR we have shown that these 5P-UTRs can be
composed of regions A and C, or of regions A, B and C
(found in kidney and lung tissues) or of regions A, C and a
part of region B (found in lung tissue only).
Another interesting feature of the human GGT gene is that
the truncated mRNAs are transcribed from a promoter
present in the intron containing the speci¢c 5P-UTRs. Trans-
fection studies show that the V3.6-kb sequence immediately
upstream of the supposed ¢rst mRNA base has a high pro-
moter activity in lung ¢broblasts while this activity is unde-
tected in ovarian cells. Promoter activity is also supported by
a 545-nucleotide sequence 3P fragment which contains AP2
and Sp1 binding sites and a GT repeat. In contrast to the
V3.6-kb fragment, the 550-bp 3P fragment exhibits a pro-
moter activity in ovarian cells, indicating that the upstream
sequences could contain a putative cis acting element confer-
ring tissue speci¢city to the promoter.
In conclusion, our data indicate that three mRNA with
di¡erent ORFs can arise from a single GGT gene: one type
contains the ‘normal’ ORF which is translated to an active
enzyme; the second contains a 22-bp insertion due to an addi-
tional unspliced intronic sequence; and ¢nally the third type
comprises the truncated mRNAs transcribed from the intronic
promoter.
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